Global Health reported its highest-ever quarterly revenue in Q1 FY27, up 26.2% year-on-year. While reported profit after tax dipped marginally, it was due to a one-off gain in the previous year. Operational metrics showed strong volume growth in both inpatient and outpatient services.
Global Health Ltd. Reports Strong Q1 FY27 Performance
Revenue Jumps 26.2% to ₹1,326.2 Cr; PAT Sees Minor Dip
Reader Takeaway: Robust revenue growth driven by volumes; watch Noida unit turnaround and Guwahati project upscaling.
What just happened
Global Health Limited has announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27). The company recorded its highest-ever quarterly total income, reaching ₹1,326.2 crore, a significant increase of 26.2% compared to ₹1,051.3 crore in Q1 FY26. EBITDA also grew by 23.5% to ₹315.3 crore. However, Profit After Tax (PAT) saw a slight decrease of 1.1%, reporting ₹157.3 crore in Q1 FY27 against ₹159.0 crore in Q1 FY26.
Why this matters
The strong revenue and EBITDA growth indicate healthy demand and improving operational efficiency for Global Health. While the reported PAT dip might seem concerning, the company clarifies it's due to a non-recurring exceptional income of ₹19.6 crore from a reversal of potential interest liability in the previous year's Q1 FY26. This suggests the core business performance is robust and is on a growth trajectory.
The backstory
Global Health, operating under the Medanta brand, is a leading healthcare provider in India. The company has been focusing on expanding its capacity and diversifying its services. The Noida unit has been a key area of focus for improvement, and the Guwahati project represents a significant future expansion.
What changes now
The company is adding capacity, with 72 new beds operationalized in Noida and Lucknow. The Noida unit is showing a clear path to profitability, reducing its EBITDA loss significantly. The Guwahati project has been upscaled to a 650-bed super-specialty hospital, indicating ambitious growth plans. The OPD Pharmacy business also continues its strong growth.
Risks to watch
Key risks include the successful execution and timely completion of the large-scale Guwahati project within the ₹970 crore capex. Continued ramp-up and profitability of the Noida unit are also crucial. Maintaining premium pricing (ARPOB) while increasing bed capacity and managing operational costs will be vital.
Peer comparison
While specific peer data isn't provided in the filing, Global Health's reported volume growth in in-patients (27.7%) and out-patients (34.5%) appears strong, outpacing general industry growth. Its ARPOB of ₹70,244 and ALOS of 2.87 days suggest a focus on complex medical procedures and quality patient care, typical of premium healthcare providers.
Context metrics (time-bound)
- Total Income: ₹1,326.2 Cr (Q1 FY27) vs ₹1,051.3 Cr (Q1 FY26) - Up 26.2%
- EBITDA: ₹315.3 Cr (Q1 FY27) vs ₹255.3 Cr (Q1 FY26) - Up 23.5%
- PAT: ₹157.3 Cr (Q1 FY27) vs ₹159.0 Cr (Q1 FY26) - Down 1.1%
- In-patient growth: 27.7% (Y-o-Y)
- Out-patient growth: 34.5% (Y-o-Y)
- New beds added: 72
- Total operational beds: 3,037
- ARPOB: ₹70,244 (up 5.5% Y-o-Y)
- ALOS: 2.87 days
- Noida unit income: ₹85.5 Cr (Q1 FY27)
- Noida unit EBITDA loss: ₹4.9 Cr (Q1 FY27)
- OPD Pharmacy revenue: ₹60.9 Cr (up 50.9% Y-o-Y)
What to track next
Investors will be looking for continued revenue growth, improvement in the Noida unit's profitability, and concrete progress updates on the ambitious Guwahati hospital project. The company's ability to sustain operational efficiencies and manage its expanding capacity will be key.